全文获取类型
收费全文 | 228007篇 |
免费 | 19972篇 |
国内免费 | 8096篇 |
专业分类
耳鼻咽喉 | 1736篇 |
儿科学 | 4373篇 |
妇产科学 | 2589篇 |
基础医学 | 30603篇 |
口腔科学 | 4108篇 |
临床医学 | 22290篇 |
内科学 | 28630篇 |
皮肤病学 | 2256篇 |
神经病学 | 9733篇 |
特种医学 | 6767篇 |
外国民族医学 | 110篇 |
外科学 | 22725篇 |
综合类 | 38512篇 |
现状与发展 | 31篇 |
一般理论 | 25篇 |
预防医学 | 12553篇 |
眼科学 | 4739篇 |
药学 | 21793篇 |
78篇 | |
中国医学 | 10802篇 |
肿瘤学 | 31622篇 |
出版年
2024年 | 189篇 |
2023年 | 2835篇 |
2022年 | 4343篇 |
2021年 | 8066篇 |
2020年 | 7417篇 |
2019年 | 7283篇 |
2018年 | 7015篇 |
2017年 | 7390篇 |
2016年 | 7931篇 |
2015年 | 8141篇 |
2014年 | 12516篇 |
2013年 | 13789篇 |
2012年 | 11764篇 |
2011年 | 13296篇 |
2010年 | 11236篇 |
2009年 | 11074篇 |
2008年 | 11215篇 |
2007年 | 12702篇 |
2006年 | 11468篇 |
2005年 | 11116篇 |
2004年 | 9674篇 |
2003年 | 8413篇 |
2002年 | 6696篇 |
2001年 | 6485篇 |
2000年 | 5370篇 |
1999年 | 4837篇 |
1998年 | 3493篇 |
1997年 | 3113篇 |
1996年 | 3112篇 |
1995年 | 3172篇 |
1994年 | 2776篇 |
1993年 | 2399篇 |
1992年 | 2036篇 |
1991年 | 1783篇 |
1990年 | 1479篇 |
1989年 | 1384篇 |
1988年 | 1309篇 |
1987年 | 1014篇 |
1986年 | 740篇 |
1985年 | 865篇 |
1984年 | 879篇 |
1983年 | 546篇 |
1982年 | 681篇 |
1981年 | 567篇 |
1980年 | 477篇 |
1979年 | 408篇 |
1978年 | 323篇 |
1977年 | 261篇 |
1976年 | 290篇 |
1975年 | 171篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
《Vaccine》2022,40(30):4038-4045
PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals. 相似文献
5.
6.
7.
Biaoming Xu Yu Chen Mingjing Peng Jin Hai Zheng Chaohui Zuo 《International journal of cancer. Journal international du cancer》2023,152(2):110-122
Pancreatic cancer (PC) is a cancer of the digestive system, and pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of all PC cases. Exosomes derived from PDAC (PDAC-exosomes) promote PDAC development and metastasis. Exosomes are nanoscale vesicles secreted by most cells, which can carry biologically active molecules and mediate communication and cargo transportation among cells. Recent studies have focused on transforming exosomes into good drug delivery systems (DDSs) to improve the clinical treatment of PDAC. This review considers PDAC as the main research object to introduce the role of PDAC-exosomes in PDAC development and metastasis. This review focuses on the following two themes: (a) the great potential of PDAC-exosomes as new diagnostic markers for PDAC, and (b) the transformation of exosomes into potential DDSs. 相似文献
8.
地鳖中的纤溶活性蛋白是从地鳖中提取的具有抗栓及抗肿瘤作用的有效成分,其口服易被上消化道酶分解从而限制了应用。采用恒流泵滴制法开发地鳖纤溶活性蛋白时间/pH依赖口服结肠靶向微囊(EnpolypHaga fibrinolytic protein oral colon targeting microcapsules, CTM-EFP)。采用单因素实验和正交实验相结合的方法寻找到包封率为60.17 % ± 2.72 %、载药量为15.50 % ± 0.44 % 的最佳配方。扫描电子显微镜(SEM)显示微囊呈球形、表面光滑,在人工肠液中24 h的累积释放度为99.53 % ± 0.69 %,在人工胃液中24 h累积释放度为7.43 ± 1.04 %,通过时间/pH依赖达到结肠靶向作用。CTM-EFP在人工肠液中的体外释放曲线符合Korsmeyer方程,提示地鳖纤溶活性蛋白(EnpolypHaga fibrinolytic protein, EFP)是通过扩散和侵蚀机制结合释放的。CTM-EFP为EFP的口服给药提供了一种新的剂型,为EFP应用于临床提供参考。 相似文献
9.
10.